Holen Sie sich die Stockscreener-App
1.61
1.52%
-0.03
Handel nachbörslich:
1.64
0.03
+1.86%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.61
24-Stunden-Volumen:
383.67K
Relative Volume:
0.56
Marktkapitalisierung:
$101.76M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-1.019
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
-6.10%
1M Leistung:
+1.57%
6M Leistung:
+27.17%
1J Leistung:
-62.27%
1-Tages-Spanne:
$1.56
$1.6892
1-Wochen-Bereich:
$1.56
$1.83
52-Wochen-Spanne:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Vergleichen Sie MGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.61 | 103.66M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
How MacroGenics Inc. stock performs in high volatility markets2025 Volume Leaders & Weekly Stock Performance Updates - newser.com
Chart based analysis of MacroGenics Inc. trends2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Can MacroGenics Inc. stock hit record highs again2025 Market Overview & Fast Moving Market Watchlists - newser.com
Will MacroGenics Inc. stock rally after Fed decisions2025 Short Interest & Consistent Profit Alerts - newser.com
When is the best time to exit MacroGenics Inc.July 2025 Momentum & Low Risk High Reward Trade Ideas - newser.com
Applying Wyckoff theory to MacroGenics Inc. stock2025 Investor Takeaways & Daily Entry Point Trade Alerts - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for MacroGenics (NASDAQ:MGNX) - MarketBeat
Bispecific Antibodies MarketGlobal Forecast 2025-2032, Profiles of Key PlayersF. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab - Yahoo Finance
Public Employees Retirement System of Ohio Has $31,000 Stake in MacroGenics, Inc. $MGNX - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
MacroGenics (NASDAQ:MGNX) and CeriBell (NASDAQ:CBLL) Head to Head Comparison - Defense World
Regression analysis insights on MacroGenics Inc. performanceDay Trade & Weekly Market Pulse Updates - newser.com
Using data models to predict MacroGenics Inc. stock movementJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Published on: 2025-10-05 06:01:39 - newser.com
Backtesting results for MacroGenics Inc. trading strategies2025 EndofYear Setup & Daily Risk Controlled Trade Plans - newser.com
Multi asset correlation models including MacroGenics Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
How currency fluctuations impact MacroGenics Inc. stockJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Developing predictive dashboards with MacroGenics Inc. dataWeekly Investment Report & Verified Entry Point Signals - newser.com
Published on: 2025-10-02 22:14:22 - newser.com
Voya Investment Management LLC Buys 40,500 Shares of MacroGenics, Inc. $MGNX - Defense World
Published on: 2025-09-30 05:12:41 - newser.com
What drives MacroGenics Inc stock priceCash Flow Trends & Amplify Gains With Picks - earlytimes.in
Goldman Sachs Group Inc. Has $251,000 Position in MacroGenics, Inc. $MGNX - MarketBeat
Extensive-Stage Small Cell Lung Cancer Pipeline 2025: Innovative Clinical Developments By 25+ Global Leaders Delveinsight Key Companies Featured Include Shanghai Henlius Biotech, Macrogenics, Inc. - Menafn.com
What drives PROG Holdings Inc AZD stock priceInterest Rate Changes & Small Capital Wealth Plans - earlytimes.in
*DJ Macrogenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA >MGNX - 富途牛牛
Strs Ohio Invests $263,000 in MacroGenics, Inc. $MGNX - MarketBeat
Intraday pattern recognizer results for MacroGenics Inc.July 2025 PostEarnings & Real-Time Volume Analysis - newser.com
Statistical indicators supporting MacroGenics Inc.’s strengthIPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Published on: 2025-09-22 05:42:18 - newser.com
Barclays Upgrades MacroGenics (NASDAQ:MGNX) to "Strong-Buy" - MarketBeat
MacroGenics (NASDAQ:MGNX) Now Covered by Analysts at Barclays - MarketBeat
Acadian Asset Management LLC Grows Position in MacroGenics, Inc. $MGNX - MarketBeat
Live market analysis of MacroGenics Inc.Quarterly Market Summary & Safe Capital Allocation Plans - newser.com
What institutional flow reveals about MacroGenics Inc.July 2025 Drop Watch & Capital Efficient Trade Techniques - newser.com
Momentum divergence signals in MacroGenics Inc. chartProfit Target & Weekly Market Pulse Alerts - newser.com
What indicators show strength in MacroGenics Inc.Weekly Investment Report & Free Growth Oriented Trading Recommendations - newser.com
Using economic indicators to assess MacroGenics Inc. potential2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):